{"news_desk": "Business", "print_page": "3", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Food and Drug Administration approves Roche's new immunotherapy drug, Tecentriq, to treat bladder cancer; drug belongs to class of medicines called checkpoint inhibitors.", "type_of_material": "News", "word_count": "1008", "lead_paragraph": "The drug, Tecentriq from Roche, works by using the body\u2019s immune system against tumors, and is the first drug of its type approved for bladder cancer.", "pub_date": "2016-05-19T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "F.D.A. Approves an Immunotherapy Drug for Bladder Cancer", "print_headline": "F.D.A. Approves Immunotherapy Drug for Treatment of Bladder Cancer"}, "snippet": "The drug, Tecentriq from Roche, works by using the body\u2019s immune system against tumors, and is the first drug of its type approved for bladder cancer.", "multimedia": [{"height": 126, "url": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 961, "url": "images/2016/05/19/business/19IMMUNE/19IMMUNE-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "961", "xlarge": "images/2016/05/19/business/19IMMUNE/19IMMUNE-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/05/19/business/19IMMUNE/19IMMUNE-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/05/19/business/food-and-drug-administration-immunotherapy-bladder-cancer.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Roche Holding AG", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Bladder Cancer", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Immune System", "name": "subject"}], "blog": [], "_id": "573ccd9338f0d81236fa7ee1", "source": "The New York Times"}